Your browser doesn't support javascript.
An ACE2-Based Decoy Inhibitor Effectively Neutralizes SARS-CoV-2 Omicron BA.5 Variant.
Zhang, Haoran; Hu, Bing; Lv, Panjing; Liu, Yahui; Guo, Meng; Wu, Zhi; Zhou, Kangping; Dai, Minglu; Yu, Xiao; Liu, Zhang; Yu, Bo; Xu, Liqiong; Guo, Min; Cai, Kun; Li, Yan.
  • Zhang H; Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
  • Hu B; Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention (Hubei CDC), Wuhan 430079, China.
  • Lv P; Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
  • Liu Y; Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
  • Guo M; Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention (Hubei CDC), Wuhan 430079, China.
  • Wu Z; Kangma Healthcode (Shanghai) Biotech, Co., Ltd., 118 Furonghua Road, Building No. 15, Shanghai 201203, China.
  • Zhou K; Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention (Hubei CDC), Wuhan 430079, China.
  • Dai M; Kangma Healthcode (Shanghai) Biotech, Co., Ltd., 118 Furonghua Road, Building No. 15, Shanghai 201203, China.
  • Yu X; Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention (Hubei CDC), Wuhan 430079, China.
  • Liu Z; Kangma Healthcode (Shanghai) Biotech, Co., Ltd., 118 Furonghua Road, Building No. 15, Shanghai 201203, China.
  • Yu B; Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention (Hubei CDC), Wuhan 430079, China.
  • Xu L; Kangma Healthcode (Shanghai) Biotech, Co., Ltd., 118 Furonghua Road, Building No. 15, Shanghai 201203, China.
  • Guo M; Kangma Healthcode (Shanghai) Biotech, Co., Ltd., 118 Furonghua Road, Building No. 15, Shanghai 201203, China.
  • Cai K; Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention (Hubei CDC), Wuhan 430079, China.
  • Li Y; Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
Viruses ; 14(11)2022 Oct 28.
Article in English | MEDLINE | ID: covidwho-2090366
ABSTRACT
The recently circulating SARS-CoV-2 Omicron BA.5 is rampaging the world with elevated transmissibility compared to the original SARS-CoV-2 strain. Immune escape of BA.5 was observed after treatment with many monoclonal antibodies, calling for broad-spectrum, immune-escape-evading therapeutics. In retrospect, we previously reported Kansetin as an ACE2 mimetic and a protein antagonist against SARS-CoV-2, which proved potent neutralization bioactivity on the Reference, Alpha, Beta, Delta, and Omicron strains of SARS-CoV-2. Since BA.5 is expected to rely on the interaction of the Spike complex with human ACE2 for cell entry, we reasonably assumed the lasting efficacy of the ACE2-mimicking Kansetin for neutralizing the new SARS-CoV-2 variant. The investigation was accordingly performed on in vitro Kansetin-Spike binding affinity by SPR and cell infection inhibition ability with pseudovirus and live virus assays. As a result, Kansetin showed dissociation constant KD and half inhibition concentration IC50 at the nanomolar to picomolar level, featuring a competent inhibition effect against the BA.5 sublineage. Conclusively, Kansetin is expected to be a promising therapeutic option against BA.5 and future SARS-CoV-2 sublineages.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin-Converting Enzyme 2 / COVID-19 Drug Treatment Type of study: Experimental Studies Topics: Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: V14112387

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin-Converting Enzyme 2 / COVID-19 Drug Treatment Type of study: Experimental Studies Topics: Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: V14112387